The role of high-density lipoprotein cholesterol in atherothrombosis

Brian G. Choi, Gemma Vilahur, Juan F. Viles-Gonzalez, Juan J. Badimon

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Despite considerable progress in the development of new therapies to control atherosclerosis and its complications, coronary heart disease (CHD) remains the number one cause of death in the Western world. While low high-density lipoprotein (HDL) has been associated with increased risk for CHD, raising HDL to reduce risk of disease has yet to be accepted as a standard therapeutic strategy. Currently available drugs that raise HDL (e.g., nicotinic acid, fibric acid derivatives, peroxisome proliferator-activated receptor agonists, and statins) also affect low-density lipoprotein (LDL) and other lipid constituents, making independent interpretation of their HDL-raising effect difficult to tease apart. Nevertheless, basic science studies suggest that HDL has multiple beneficial effects, and current efforts to develop new pharmacologic products with potent HDL-elevating effects may herald a day when HDL elevation becomes part of standard management of atherosclerotic diseases.

Original languageEnglish (US)
Pages (from-to)690-701
Number of pages12
JournalMount Sinai Journal of Medicine
Issue number4
StatePublished - Jul 1 2006


  • Atherosclerosis
  • Cholesterol ester transfer protein inhibitor
  • Coronary heart disease
  • Dyslipidemia
  • Fibrate
  • HDL elevating therapy
  • High-density lipoprotein cholesterol
  • Nicotinic acid
  • Peroxisome proliferator-activated receptor ligands
  • Statin

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'The role of high-density lipoprotein cholesterol in atherothrombosis'. Together they form a unique fingerprint.

Cite this